Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

2 Feb 2018

Abstract excerpt

The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune Bullous Skin Diseases
Share to Drug-Induced Adverse Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29392710
DOI: 10.1002/cpt.1004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 UpdatePMID 29392710Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.Semantic proximity Read ↗

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

The risk of cutaneous adverse reactions among patients with the <i>HLA-A* 31:01</i> allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective reviewSemantic proximity Read ↗

Associations of HLA genetic variants with carbamazepine-induced cutaneous adverse drug reactions: An updated meta-analysis.Semantic proximity Read ↗

An update on HLA alleles associated with adverse drug reactions.Semantic proximity Read ↗

The HLA-A*31:01 allele: influence on carbamazepine treatmentSemantic proximity Read ↗

HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review.Semantic proximity Read ↗

HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese.Semantic proximity Read ↗

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.Semantic proximity Read ↗

Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.Semantic proximity Read ↗

Genetic variants associated with severe cutaneous adverse drug reactions induced by carbamazepine.Semantic proximity Read ↗

Unraveling the genetic link: an umbrella review on HLA-B*15:02 and antiepileptic drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.